Cambridge Healthtech Institute’s 4th Annual

mRNA & Emerging Oligonucleotide Modalities

Next-Generation RNA Therapies for Increased Efficacy, Stability, and Targeted Delivery

March 18-19, 2026

Cambridge Healthtech Institute’s conference on mRNA & Emerging Oligonucleotide Modalities shines a light on the incredible creativity of chemists and biologists in designing targeted oligo therapies. Equipped with new chemistries, AI/ML-enabled design predictions, engineering and editing tools, and novel delivery mechanisms, scientists are modifying naturally occurring mRNA, tRNA, saRNA, circular RNA, and non-coding RNA to overcome some of the limitations in existing therapies. The talks highlight how new oligo modalities are being developed to improve stability, dosing, frequency of administration, and toxicity, making it one of the most promising areas in drug development.

Coverage will include, but is not limited to:

Novel oligo modifications and chemistries for improving efficacy and stability
Use of mRNA, tRNA, saRNA, circular RNA, non-coding RNA as targeted therapies for tissue-specific impact
New engineering and AI/machine learning tools for increasing oligo potency and safety
Conjugation, encapsulation, and formulations for enhanced tissue and cell-type specific delivery
Using various pathways (conjugation, degradation, activation, splicing) to go after challenging drug targets
Exploring applications in oncology, immunology, infectious, rare diseases and beyond

The deadline for priority consideration is September 5, 2025.

Submit a Proposal »

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: